Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q2 EPS of $1.56, $1.80 worse than the analyst estimate of $3.36. Revenue for the quarter came in at $74.1 million versus the consensus estimate of $116.95 million.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.